Compare Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Tax Managed Fund FTSE Developed Markets ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.26 (market cap $323.80B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 2.5× Vertex Pharmaceuticals Incorporated's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| VEA | VRTX | |
|---|---|---|
Market Cap | $323.80B | $128.16B |
Volume | 9,762,021 | 806,603 |
52-Week High | $73.79 | $557.96 |
52-Week Low | $58.90 | $407.37 |
Typical Hold Time | 131 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VEA, the Vanguard FTSE Developed Markets ETF, trades at $70.26, down 1.2% on the day amid a bearish technical signal. The ETF provides cost-efficient exposure to developed markets outside the U.S., with a 0.03% expense ratio and competitive dividend yield. Recent news highlights institutional activity, with firms like Allianz Asset Management increasing stakes while others trimmed positions.
The outlook remains mixed, with technical indicators signaling caution but fundamental strengths in low costs and diversification. Key risks include global market volatility and currency fluctuations. Investors should weigh the ETF's stable, income-oriented profile against near-term bearish momentum.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
